{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:04:32Z","timestamp":1791846272507,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5P30-CA014051"],"award-info":[{"award-number":["5P30-CA014051"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5P30-CA014051"],"award-info":[{"award-number":["5P30-CA014051"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5P30-CA014051"],"award-info":[{"award-number":["5P30-CA014051"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5P30-CA014051"],"award-info":[{"award-number":["5P30-CA014051"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R61AI161805"],"award-info":[{"award-number":["R61AI161805"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R61AI161805"],"award-info":[{"award-number":["R61AI161805"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R61AI161805"],"award-info":[{"award-number":["R61AI161805"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41565-025-02044-6","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:02:54Z","timestamp":1762509774000},"page":"1831-1842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-5534","authenticated-orcid":false,"given":"Arnab","family":"Rudra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5614-2313","authenticated-orcid":false,"given":"Akash","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-1613","authenticated-orcid":false,"given":"Kaelan","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9687-0953","authenticated-orcid":false,"given":"Amy","family":"Deik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8086-095X","authenticated-orcid":false,"given":"Jiyeon","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1422-5062","authenticated-orcid":false,"given":"Hasan Mansour A","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6007-1988","authenticated-orcid":false,"given":"Quang Trung Chinh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Danko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allegra","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1024-7176","authenticated-orcid":false,"given":"Michaela","family":"Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clary B.","family":"Clish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8725-1870","authenticated-orcid":false,"given":"Jeffery B.","family":"Klauda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-0492","authenticated-orcid":false,"given":"Robert","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5629-4798","authenticated-orcid":false,"given":"Daniel G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2044_CR1","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","volume":"23","author":"N Pardi","year":"2024","unstructured":"Pardi, N. & Krammer, F. mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities. Nat. Rev. Drug Discov. 23, 838\u2013861 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2044_CR2","unstructured":"COVID-19, vaccinations (broken down by manufacturer). Our World in Data https:\/\/ourworldindata.org\/grapher\/covid-vaccine-doses-by-manufacturer (accessed 25 May 2025)."},{"key":"2044_CR3","first-page":"183","volume":"41","author":"N Warne","year":"2023","unstructured":"Warne, N. et al. Delivering 3 billion doses of Comirnaty in 2021. Nat. Biotechnol. 41, 183\u2013188 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2044_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2044_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01041-z","author":"A Gupta","year":"2024","unstructured":"Gupta, A., Rudra, A., Reed, K., Langer, R. & Anderson, D. G. Advanced technologies for the development of infectious disease vaccines. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-024-01041-z (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2044_CR6","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39, 2190\u20132200 (2021).","journal-title":"Vaccine"},{"key":"2044_CR7","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1016\/S2214-109X(22)00075-4","volume":"10","author":"GVT Roozen","year":"2022","unstructured":"Roozen, G. V. T., Roukens, A. H. E. & Roestenberg, M. COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness. Lancet Glob. Health 10, e570\u2013e573 (2022).","journal-title":"Lancet Glob. Health"},{"key":"2044_CR8","doi-asserted-by":"publisher","first-page":"2190690","DOI":"10.1080\/21645515.2023.2190690","volume":"19","author":"P Yassini","year":"2023","unstructured":"Yassini, P. et al. Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults. Hum. Vaccin. Immunother. 19, 2190690 (2023).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2044_CR9","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","volume":"55","author":"R Verbeke","year":"2022","unstructured":"Verbeke, R., Hogan, M. J., Lor\u00e9, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993\u20132005 (2022).","journal-title":"Immunity"},{"key":"2044_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1\u201311 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2044_CR11","unstructured":"Public assessment report authorisation for temporary supply COVID-19 mRNA vaccine BNT162b2 (BNT162b2 RNA) concentrate for solution for injection. MHRA https:\/\/assets.publishing.service.gov.uk\/media\/63529601e90e07768265c115\/COVID-19_mRNA_Vaccine_BNT162b2__UKPAR___PFIZER_BIONTECH_ext_of_indication_11.6.2021.pdf (accessed 25 May 2025)."},{"key":"2044_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00650-3","author":"Y Oda","year":"2024","unstructured":"Oda, Y. et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet Infect. Dis. https:\/\/doi.org\/10.1016\/S1473-3099(23)00650-3 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2044_CR13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"2044_CR14","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/s41587-019-0247-3","volume":"37","author":"L Miao","year":"2019","unstructured":"Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174\u20131185 (2019).","journal-title":"Nat. Biotechnol."},{"key":"2044_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01082-6","author":"B Li","year":"2023","unstructured":"Li, B. et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-023-01082-6 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"2044_CR16","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1021\/acs.nanolett.2c04883","volume":"23","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. STING agonist-derived LNP-mRNA vaccine enhances protective immunity against SARS-CoV-2. Nano Lett. 23, 2593\u20132600 (2023).","journal-title":"Nano Lett."},{"key":"2044_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41565-023-01404-4","volume":"18","author":"X Han","year":"2023","unstructured":"Han, X. et al. Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines. Nat. Nanotechnol. 18, 1105\u20131114 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"2044_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207486","volume":"34","author":"J Yan","year":"2022","unstructured":"Yan, J. et al. Nanomaterials-mediated co-stimulation of toll-like receptors and CD40 for antitumor immunity. Adv. Mater. 34, 2207486 (2022).","journal-title":"Adv. Mater."},{"key":"2044_CR19","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., S. Arunachalam, P. & O\u2019Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2044_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122243","volume":"301","author":"RL Goldman","year":"2023","unstructured":"Goldman, R. L. et al. Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications. Biomaterials 301, 122243 (2023).","journal-title":"Biomaterials"},{"key":"2044_CR21","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1002\/adma.201505822","volume":"28","author":"OS Fenton","year":"2016","unstructured":"Fenton, O. S. et al. Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv. Mater. 28, 2939\u20132943 (2016).","journal-title":"Adv. Mater."},{"key":"2044_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nbt1402","volume":"26","author":"A Akinc","year":"2008","unstructured":"Akinc, A. et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561\u2013569 (2008).","journal-title":"Nat. Biotechnol."},{"key":"2044_CR23","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1073\/pnas.0910603106","volume":"107","author":"KT Love","year":"2010","unstructured":"Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864\u20131869 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2044_CR24","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1073\/pnas.1322937111","volume":"111","author":"Y Dong","year":"2014","unstructured":"Dong, Y. et al. Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc. Natl Acad. Sci. USA 111, 3955\u20133960 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2044_CR25","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.1038\/ncomms5277","volume":"5","author":"KA Whitehead","year":"2014","unstructured":"Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).","journal-title":"Nat. Commun."},{"key":"2044_CR26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2309472120","volume":"120","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proc. Natl Acad. Sci. USA 120, e2309472120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2044_CR27","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1021\/jacs.2c10670","volume":"145","author":"G Tilstra","year":"2023","unstructured":"Tilstra, G. et al. Iterative design of ionizable lipids for intramuscular mRNA delivery. J. Am. Chem. Soc. 145, 2294\u20132304 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2044_CR28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/s41551-024-01267-7","volume":"8","author":"X Han","year":"2024","unstructured":"Han, X. et al. Optimization of the activity and biodegradability of ionizable lipids for mRNA delivery via directed chemical evolution. Nat. Biomed. Eng. 8, 1412\u20131424 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"2044_CR29","doi-asserted-by":"publisher","first-page":"22137","DOI":"10.1038\/srep22137","volume":"6","author":"B Li","year":"2016","unstructured":"Li, B. et al. Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA. Sci. Rep. 6, 22137 (2016).","journal-title":"Sci. Rep."},{"key":"2044_CR30","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1021\/acsami.7b15982","volume":"10","author":"JB Miller","year":"2018","unstructured":"Miller, J. B., Kos, P., Tieu, V., Zhou, K. & Siegwart, D. J. Development of cationic quaternary ammonium sulfonamide amino lipids for nucleic acid delivery. ACS Appl. Mater. Interfaces 10, 2302\u20132311 (2018).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2044_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202106727","volume":"32","author":"M Cornebise","year":"2022","unstructured":"Cornebise, M. et al. Discovery of a novel amino lipid that improves lipid nanoparticle performance through specific interactions with mRNA. Adv. Funct. Mater. 32, 2106727 (2022).","journal-title":"Adv. Funct. Mater."},{"key":"2044_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.2133\/dmpk.DMPK-12-RV-042","volume":"27","author":"T Fukami","year":"2012","unstructured":"Fukami, T. & Yokoi, T. The emerging role of human esterases. Drug Metab. Pharmacokinet. 27, 466\u2013477 (2012).","journal-title":"Drug Metab. Pharmacokinet."},{"key":"2044_CR33","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1021\/jo062586z","volume":"72","author":"F Brotzel","year":"2007","unstructured":"Brotzel, F., Ying, C. C. & Mayr, H. Nucleophilicities of primary and secondary amines in water. J. Org. Chem. 72, 3679\u20133688 (2007).","journal-title":"J. Org. Chem."},{"key":"2044_CR34","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","volume":"107","author":"J Heyes","year":"2005","unstructured":"Heyes, J., Palmer, L., Bremner, K. & MacLachlan, I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107, 276\u2013287 (2005).","journal-title":"J. Control. Release"},{"key":"2044_CR35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nbt.1602","volume":"28","author":"SC Semple","year":"2010","unstructured":"Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172\u2013176 (2010).","journal-title":"Nat. Biotechnol."},{"key":"2044_CR36","doi-asserted-by":"publisher","first-page":"7300","DOI":"10.1021\/acs.nanolett.5b02497","volume":"15","author":"KJ Kauffman","year":"2015","unstructured":"Kauffman, K. J. et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 15, 7300\u20137306 (2015).","journal-title":"Nano Lett."},{"key":"2044_CR37","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1021\/nn301922x","volume":"6","author":"KA Whitehead","year":"2012","unstructured":"Whitehead, K. A. et al. In vitro\u2013in vivo translation of lipid nanoparticles for hepatocellular siRNA delivery. ACS Nano 6, 6922\u20136929 (2012).","journal-title":"ACS Nano"},{"key":"2044_CR38","doi-asserted-by":"publisher","first-page":"8529","DOI":"10.1002\/anie.201203263","volume":"51","author":"M Jayaraman","year":"2012","unstructured":"Jayaraman, M. et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew. Chem. Int. Ed. 51, 8529\u20138533 (2012).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2044_CR39","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","volume":"22","author":"JD Finn","year":"2018","unstructured":"Finn, J. D. et al. A single administration of CRISPR\u2013Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing. Cell Rep. 22, 2227\u20132235 (2018).","journal-title":"Cell Rep."},{"key":"2044_CR40","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"2044_CR41","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).","journal-title":"iScience"},{"key":"2044_CR42","doi-asserted-by":"publisher","first-page":"102083","DOI":"10.1016\/j.omtn.2023.102083","volume":"35","author":"KJ Hassett","year":"2024","unstructured":"Hassett, K. J. et al. mRNA vaccine trafficking and resulting protein expression after intramuscular administration. Mol. Ther. Nucleic Acids 35, 102083 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2044_CR43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.molmed.2022.04.007","volume":"28","author":"IP Trougakos","year":"2022","unstructured":"Trougakos, I. P. et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol. Med. 28, 542\u2013554 (2022).","journal-title":"Trends Mol. Med."},{"key":"2044_CR44","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/hep.32572","volume":"76","author":"C Efe","year":"2022","unstructured":"Efe, C. et al. Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology 76, 1576\u20131586 (2022).","journal-title":"Hepatology"},{"key":"2044_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/biomedicines12010059","volume":"12","author":"I Pateev","year":"2023","unstructured":"Pateev, I., Seregina, K., Ivanov, R. & Reshetnikov, V. Biodistribution of RNA vaccines and of their products: evidence from human and animal studies. Biomedicines 12, 59 (2023).","journal-title":"Biomedicines"},{"key":"2044_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/srep25377","volume":"6","author":"D Zhang","year":"2016","unstructured":"Zhang, D. et al. Simplified quantification method for in vivo SPECT\/CT imaging of asialoglycoprotein receptor with 99mTc-p(VLA-co-VNI) to assess and stage hepatic fibrosis in mice. Sci. Rep. 6, 25377 (2016).","journal-title":"Sci. Rep."},{"key":"2044_CR47","doi-asserted-by":"publisher","first-page":"8943","DOI":"10.1073\/pnas.1014501108","volume":"108","author":"K Welsher","year":"2011","unstructured":"Welsher, K., Sherlock, S. P. & Dai, H. Deep-tissue anatomical imaging of mice using carbon nanotube fluorophores in the second near-infrared window. Proc. Natl Acad. Sci. USA 108, 8943\u20138948 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2044_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2022.116143","volume":"451","author":"K Broudic","year":"2022","unstructured":"Broudic, K. et al. Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery. Toxicol. Appl. Pharm. 451, 116143 (2022).","journal-title":"Toxicol. Appl. Pharm."},{"key":"2044_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"2044_CR50","doi-asserted-by":"publisher","first-page":"e2217533119","DOI":"10.1073\/pnas.2217533119","volume":"119","author":"S Pecetta","year":"2022","unstructured":"Pecetta, S. & Rappuoli, R. mRNA, the beginning of a new influenza vaccine game. Proc. Natl Acad. Sci. USA 119, e2217533119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2044_CR51","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2336357","volume":"20","author":"CA Russell","year":"2024","unstructured":"Russell, C. A. et al. Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines. Hum. Vaccin. Immunother. 20, 2336357 (2024).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2044_CR52","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.1073\/pnas.1805268115","volume":"115","author":"AL Fink","year":"2018","unstructured":"Fink, A. L., Engle, K., Ursin, R. L., Tang, W.-Y. & Klein, S. L. Biological sex affects vaccine efficacy and protection against influenza in mice. Proc. Natl Acad. Sci. USA 115, 12477\u201312482 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2044_CR53","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/01.shk.0000142249.08135.e9","volume":"22","author":"H Watanabe","year":"2004","unstructured":"Watanabe, H., Numata, K., Ito, T., Takagi, K. & Matsukawa, A. Innate immune response in th1- and th2-dominant mouse strains. Shock 22, 460\u2013466 (2004).","journal-title":"Shock"},{"key":"2044_CR54","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccin. Immunol. 17, 1055\u20131065 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"2044_CR55","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"2044_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature12978","volume":"507","author":"H Liu","year":"2014","unstructured":"Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519\u2013522 (2014).","journal-title":"Nature"},{"key":"2044_CR57","doi-asserted-by":"publisher","first-page":"13582","DOI":"10.1002\/anie.201809056","volume":"57","author":"OS Fenton","year":"2018","unstructured":"Fenton, O. S. et al. Customizable lipid nanoparticle materials for the delivery of siRNAs and mRNAs. Angew. Chem. Int. Ed. 57, 13582\u201313586 (2018).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2044_CR58","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.ymthe.2017.08.006","volume":"25","author":"F Liang","year":"2017","unstructured":"Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 25, 2635\u20132647 (2017).","journal-title":"Mol. Ther."},{"key":"2044_CR59","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1021\/bc00023a012","volume":"4","author":"J Haensler","year":"1993","unstructured":"Haensler, J. & Szoka, F. C. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem. 4, 372\u2013379 (1993).","journal-title":"Bioconjug. Chem."},{"key":"2044_CR60","doi-asserted-by":"publisher","first-page":"6904","DOI":"10.1039\/C8TB00967H","volume":"6","author":"T Bus","year":"2018","unstructured":"Bus, T., Traeger, A. & Schubert, U. S. The great escape: how cationic polyplexes overcome the endosomal barrier. J. Mater. Chem. B 6, 6904\u20136918 (2018).","journal-title":"J. Mater. Chem. B"},{"key":"2044_CR61","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/09205063.2012.690282","volume":"24","author":"EC Freeman","year":"2013","unstructured":"Freeman, E. C., Weiland, L. M. & Meng, W. S. Modeling the proton sponge hypothesis: examining proton sponge effectiveness for enhancing intracellular gene delivery through multiscale modeling. J. Biomater. Sci. Polym. Ed. 24, 398\u2013416 (2013).","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"2044_CR62","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1021\/ar3000162","volume":"45","author":"J Nguyen","year":"2012","unstructured":"Nguyen, J. & Szoka, F. C. Nucleic acid delivery: the missing pieces of the puzzle?. Acc. Chem. Res. 45, 1153\u20131162 (2012).","journal-title":"Acc. Chem. Res."},{"key":"2044_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2019.08.004","volume":"144","author":"S Patel","year":"2019","unstructured":"Patel, S. et al. Brief update on endocytosis of nanomedicines. Adv. Drug Deliv. Rev. 144, 90\u2013111 (2019).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2044_CR64","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/sj.gt.3301506","volume":"8","author":"IM Hafez","year":"2001","unstructured":"Hafez, I. M., Maurer, N. & Cullis, P. R. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8, 1188\u20131196 (2001).","journal-title":"Gene Ther."},{"key":"2044_CR65","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1515\/hsz-2014-0126","volume":"395","author":"S Finger","year":"2014","unstructured":"Finger, S., Schwieger, C., Arouri, A., Kerth, A. & Blume, A. Interaction of linear polyamines with negatively charged phospholipids: the effect of polyamine charge distance. Biol. Chem. 395, 769\u2013778 (2014).","journal-title":"Biol. Chem."},{"key":"2044_CR66","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1039\/D1DD00025J","volume":"1","author":"HA Aty","year":"2022","unstructured":"Aty, H. A. et al. Machine learning platform for determining experimental lipid phase behaviour from small angle X-ray scattering patterns by pre-training on synthetic data. Digit. Discov. 1, 98\u2013107 (2022).","journal-title":"Digit. Discov."},{"key":"2044_CR67","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s41563-024-01867-3","volume":"23","author":"B Li","year":"2024","unstructured":"Li, B. et al. Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nat. Mater. 23, 1002\u20131008 (2024).","journal-title":"Nat. Mater."},{"key":"2044_CR68","doi-asserted-by":"publisher","unstructured":"Witten, J. et al. Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02490-y (2024).","DOI":"10.1038\/s41587-024-02490-y"},{"key":"2044_CR69","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1021\/ct300400x","volume":"8","author":"RB Best","year":"2012","unstructured":"Best, R. B. et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone \u03c6, \u03c8 and side-chain \u03c71 and \u03c72 dihedral angles. J. Chem. Theory Comput. 8, 3257\u20133273 (2012).","journal-title":"J. Chem. Theory Comput."},{"key":"2044_CR70","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/jcc.20082","volume":"25","author":"AD Mackerell","year":"2004","unstructured":"Mackerell, A. D. Empirical force fields for biological macromolecules: overview and issues. J. Comput. Chem. 25, 1584\u20131604 (2004).","journal-title":"J. Comput. Chem."},{"key":"2044_CR71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chemphyslip.2015.07.014","volume":"192","author":"RM Venable","year":"2015","unstructured":"Venable, R. M., Brown, F. L. H. & Pastor, R. W. Mechanical properties of lipid bilayers from molecular dynamics simulation. Chem. Phys. Lipids 192, 60\u201374 (2015).","journal-title":"Chem. Phys. Lipids"},{"key":"2044_CR72","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.1021\/acs.chemrev.8b00384","volume":"119","author":"AN Leonard","year":"2019","unstructured":"Leonard, A. N., Wang, E., Monje-Galvan, V. & Klauda, J. B. Developing and testing of lipid force fields with applications to modeling cellular membranes. Chem. Rev. 119, 6227\u20136269 (2019).","journal-title":"Chem. Rev."},{"key":"2044_CR73","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1021\/jp101759q","volume":"114","author":"JB Klauda","year":"2010","unstructured":"Klauda, J. B. et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. Chem. B 114, 7830\u20137843 (2010).","journal-title":"J. Phys. Chem. B"},{"key":"2044_CR74","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/jcc.540040211","volume":"4","author":"BR Brooks","year":"1983","unstructured":"Brooks, B. R. et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4, 187\u2013217 (1983).","journal-title":"J. Comput. Chem."},{"key":"2044_CR75","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks, B. R. et al. CHARMM: the biomolecular simulation program. J. Comput. Chem. 30, 1545\u20131614 (2009).","journal-title":"J. Comput. Chem."},{"key":"2044_CR76","doi-asserted-by":"publisher","first-page":"9976","DOI":"10.1021\/acs.jpcb.4c04100","volume":"128","author":"W Hwang","year":"2024","unstructured":"Hwang, W. et al. CHARMM at 45: enhancements in accessibility, functionality, and speed. J. Phys. Chem. B 128, 9976\u201310042 (2024).","journal-title":"J. Phys. Chem. B"},{"key":"2044_CR77","doi-asserted-by":"publisher","first-page":"9845","DOI":"10.1039\/C9CP01532A","volume":"21","author":"P Smith","year":"2019","unstructured":"Smith, P., Ziolek, R. M., Gazzarrini, E., Owen, D. M. & Lorenz, C. D. On the interaction of hyaluronic acid with synovial fluid lipid membranes. Phys. Chem. Chem. Phys. 21, 9845\u20139857 (2019).","journal-title":"Phys. Chem. Chem. Phys."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02044-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02044-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02044-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T01:02:08Z","timestamp":1766538128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-025-02044-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2044"],"URL":"https:\/\/doi.org\/10.1038\/s41565-025-02044-6","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.G.A. discloses potential competing interests due to his advising (past and present), Alnylam, Sanofi, Translate Bio, oRNA Therapeutics and Combined Therapeutics. R.L. discloses potential competing interests due to his advising (past and present) Alnylam, Moderna and Combined Therapeutics. For a list of entities with which R.L. is involved, compensated or uncompensated, see\n                      \n                      . Patent applications covering aspects of this work have been filed by D.G.A., A.R., A.G. and K.R. with application numbers 18\/396,181 and 63\/614,873, and are currently pending. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}